Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
$4.34
$4.34
$1.37
$4.58
$37.54M0.7496,055 shsN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$1.58
+0.4%
$1.36
$0.95
$5.99
$18.10M1.4380,181 shs33,364 shs
Heatwurx Inc. stock logo
PCSA
Heatwurx
$0.19
+2.4%
$0.26
$0.15
$3.10
$2.32M1.34.94 million shs2.85 million shs
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
$1.10
$1.08
$0.59
$8.08
$36.47M0.1701,788 shsN/A
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
0.00%0.00%0.00%0.00%+97.27%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
0.00%+7.95%+3.68%+55.89%-69.63%
Heatwurx Inc. stock logo
PCSA
Heatwurx
0.00%-1.63%-33.52%-43.24%-89.34%
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
MARKER THERAPEUTICS, INC. stock logo
MRKR
MARKER THERAPEUTICS
3.211 of 5 stars
3.83.00.03.90.00.80.6
Heatwurx Inc. stock logo
PCSA
Heatwurx
3.668 of 5 stars
3.55.00.00.02.51.71.3
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
3.00
Buy$8.6398.73% Upside
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
3.50
Strong Buy$13.17735.45% Upside
Heatwurx Inc. stock logo
PCSA
Heatwurx
3.00
Buy$2.00936.27% Upside
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest LUMO, PCSA, STSA, and MRKR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Heatwurx Inc. stock logo
PCSA
Heatwurx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $2.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
$2.21M17.02N/AN/A$3.45 per share1.26
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$6.59M2.71N/AN/A$1.73 per share0.91
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/AN/AN/AN/A$0.46 per shareN/A
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/AN/AN/AN/A$1.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
-$34.03M-$4.29N/AN/AN/A-1,583.49%-233.03%-129.88%N/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$10.73M-$1.33N/AN/AN/A-224.46%-101.87%-83.02%8/13/2025 (Estimated)
Heatwurx Inc. stock logo
PCSA
Heatwurx
-$11.85M-$3.08N/AN/AN/AN/A-319.56%-232.40%8/12/2025 (Estimated)
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
-$70.06M-$2.01N/AN/AN/AN/A-115.24%-102.26%N/A

Latest LUMO, PCSA, STSA, and MRKR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Heatwurx Inc. stock logo
PCSA
Heatwurx
-$0.77-$0.30+$0.47-$0.30N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
N/AN/AN/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/AN/AN/AN/AN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/AN/AN/AN/AN/A
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
N/A
2.66
2.66
MARKER THERAPEUTICS, INC. stock logo
MRKR
MARKER THERAPEUTICS
N/A
6.79
6.79
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/A
2.93
2.93
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/A
7.44
7.44

Institutional Ownership

CompanyInstitutional Ownership
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
33.99%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
22.39%
Heatwurx Inc. stock logo
PCSA
Heatwurx
91.93%
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
93.26%

Insider Ownership

CompanyInsider Ownership
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
25.40%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
14.50%
Heatwurx Inc. stock logo
PCSA
Heatwurx
9.60%
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
31.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lumos Pharma, Inc. stock logo
LUMO
Lumos Pharma
308.65 million6.45 millionNot Optionable
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
6011.32 million9.67 millionNot Optionable
Heatwurx Inc. stock logo
PCSA
Heatwurx
2011.88 million10.74 millionNot Optionable
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
2133.15 million22.81 millionNot Optionable

Recent News About These Companies

FDA clears Satsuma’s Atzumi for migraine
Satsuma Pharmaceuticals Inc (STSA)
SNBL’s Subsidiary Resubmits Migraine Drug Application
Satsuma, AL Weather Conditions
Satsuma, FL Weather Conditions

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lumos Pharma stock logo

Lumos Pharma NASDAQ:LUMO

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.

Marker Therapeutics stock logo

Marker Therapeutics NASDAQ:MRKR

$1.58 +0.01 (+0.38%)
As of 07/3/2025 03:16 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Heatwurx stock logo

Heatwurx NASDAQ:PCSA

$0.19 +0.00 (+2.39%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$0.19 0.00 (0.00%)
As of 07/3/2025 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

Satsuma Pharmaceuticals stock logo

Satsuma Pharmaceuticals NASDAQ:STSA

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.